IL2 and acute myeloid leukemia: While the efficacy of midostaurin and quizartinib for remission maintenance in FLT3-mutated AML remains to be formally validated, oral azacitidine and HDC/IL-2 were only administered after the completion of chemotherapy in the pivotal phase III trials (QUAZAR and 0201, respectively) ascertaining that these regimens prevent relapse in the postchemotherapy phase.